Balloon Sinuplasty

Balloon Sinuplasty with Medical Management in the Office is an effective treatment option for RARS patients. In a recent randomized, controlled study with RARS patients, balloon sinus dilation (BSD) performed in office (IO) with MM was found to be superior when compared to MM alone. The change in patient-reported quality of life (QOL) improved in more than 70% over 24 weeks, with respect to Medical Management only. The improvement was significantly greater in patients treated  with BSD plus MM (p=0.0424). 37.3% BSD with MM 21.8% MM alone

The primary outcome was the change in Chronic Sinusitis Survey (CSS) score from baseline to 24 weeks. The Secondary endpoints included comparisons of Rhinosinusitis Disability Index (RSDI) score, medication usage, medical care visits, and sinus infections. Both of Quality of Life (QOL) outcome measures – CSS and RSDI indicate superiority of the BSD+MM group compared to the MM alone group for Recurrent Acute Sinus Sufferers. Positive Patient outcomes were sustained through 48 weeks post-treatment follow up.¹

We are excited to share this news with you. For more information contact your local Acclarent representative or call 1-877-775-2789

¹ Sikand A, Ehmer DR, Stolovitsky JP, et al. In-office balloon sinus dilation versus medical therapy for recurrent acute rhinosinusitis: a randomized, placebo-controlled study. Int Forum Allergy Rhinol. 2019;9:140–148. ACCLARENT® Balloon Sinuplasty Devices are intended for use by or under the direction of a physician who is trained in the use of Acclarent Technology. ACCLARENT® Balloon Sinuplasty Device use has described risks, including tissue and mucosal trauma, infection, or possible orbital injury. Prior to use, it is important to read the Instructions for Use and to understand the contraindications, warnings, and precautions associated with these devices, as well as all products mentioned on this resource. Caution: Federal (US) law restricts the sale, distribution or use of these devices to, by or on the order of a physician. Third party trademarks used herein are trademarks of their respective owners. This content is intended for audience within the US only. © Acclarent, Inc. 2019. 115365-190529